Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT: Panzyga for Prevention of Major Infection in Patients With Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions
NCT07220915Phase 3Recruiting
- Sponsor
- Octapharma
- Start
- Jun 2026
- Primary completion
- Dec 2029
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
A Phase 3 trial of intravenous immunoglobulin G in Infection, sponsored by Octapharma. Started Jun 2026; status: recruiting.
02
Drugs
intravenous immunoglobulin G
03
Conditions
Infection
Beyond the preview
Go deeper on NCT07220915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220915.